The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

June 22, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270FDA Draft Guidance for Osteoporosis Treatments
The U.S. Food and Drug Administration (FDA) has issued a new draft guidance document for osteoporosis drug development.1 The FDA is asking that, in addition to performing nonclinical pharmacology and toxicology studies, drug manufacturers conduct long-term, nonclinical bone quality studies for new drugs and biologics for osteoporosis indications. These studies are necessary because of concerns about the long-term adverse effects of pharmaceuticals on bone quality. Additionally, there are no validated and reliable methods for noninvasive bone quality assessment in humans. These studies are needed to determine whether osteoporosis treatments result in poorer bone quality when taken for a long time.

You Might Also Like
  • FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain
Also By This Author
  • Baricitinib Studied as Possible COVID-19 Treatment; Plus Ranitidine Removed from U.S. Market

According to the FDA, for most of these pharmaceuticals, manufacturers need to investigate the agent in two different animal species. In the guidance, specific recommendations are made for the indication of postmenopausal osteoporosis, the most commonly treated form of osteoporosis. Some biologics may be exempt from the two species recommendation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The guidance has been issued for public comment purposes only. Comments and suggestions regarding the draft document should be submitted within 60 days of the publication of the notice in the Federal Register announcing the availability of the draft guidance. Electronic comments should be submitted to www.regulations.gov. Written comments should be sent to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number (HFA-305) listed in the notice of availability that publishes in the Federal Register.

Immediate-Release Benzhydrocodone Rejected by FDA
An abuse-deterrent, immediate-release, fixed-dose combination of benzhydrocodone (a hydrocodone prodrug and benzoic acid) plus acetaminophen (Apadaz, KP201/APAP) submitted to the FDA for approval to treat short-term acute pain has received a complete response letter.2 In the letter, the FDA states that the benzhydrocodone/acetaminophen (Apadaz) treatment is not ready for approval in its current form.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In May, the FDA’s Anesthetic and Analgesic Drug Products and Risk Management Advisory Committees voted 16–4 to approve the agent, but voted 18–2 that the analgesic should not have abuse deterrent labeling.3 The manufacturer plans to meet with the FDA to discuss future options for the agent.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. U.S. Food and Drug Administration. Osteoporosis: Nonclinical evaluation of drugs intended for treatment—guidance for industry (draft guidance). 2016 Jun 13.
  2. KemPharm Inc. News release: FDA issues complete response letter for Apadaz new drug application. 2016 Jun 13.
  3. Staff. FDA rejects KemPharm’s Apadaz. BioCentury. 2016 Jun 13.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Conditions, Drug Updates Tagged With: Benzhydrocodone hydrochloride, Chronic pain, FDA, Food and Drug Administration, Guidelines, Osteoporosis, postmenopause, Regulation

You Might Also Like:
  • FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval
  • Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
  • FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)